Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 516

1.

Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.

Gerschenson M, Kim C, Berzins B, Taiwo B, Libutti DE, Choi J, Chen D, Weinstein J, Shore J, da Silva B, Belsey E, McComsey GA, Murphy RL.

J Antimicrob Chemother. 2009 Jun;63(6):1244-50. doi: 10.1093/jac/dkp100. Epub 2009 Mar 25.

PMID:
19321503
2.

The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.

Milinkovic A, Martinez E, López S, de Lazzari E, Miró O, Vidal S, Blanco JL, Garrabou G, Laguno M, Arnaiz JA, Leon A, Larrousse M, Lonca M, Mallolas J, Gatell JM.

Antivir Ther. 2007;12(3):407-15.

PMID:
17591031
3.

Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy.

Ananworanich J, Nuesch R, Côté HC, Kerr SJ, Hill A, Jupimai T, Laopraynak N, Saenawat S, Ruxrungtham K, Hirschel B.

J Antimicrob Chemother. 2008 Jun;61(6):1340-3. doi: 10.1093/jac/dkn097. Epub 2008 Mar 12.

PMID:
18339636
4.

Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.

Rosso R, Nasi M, Di Biagio A, Repetto E, Dentone C, Pinti M, Nemes E, Ferraresi R, Mussini C, Esposito R, Viscoli C, Cossarizza A.

Pediatr Infect Dis J. 2008 Jan;27(1):17-21.

PMID:
18162932
5.

Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).

Negredo E, Miró O, Rodríguez-Santiago B, Garrabou G, Estany C, Masabeu A, Force L, Barrufet P, Cucurull J, Domingo P, Alonso-Villaverde C, Bonjoch A, Morén C, Pérez-Alvarez N, Clotet B; MULTINEKA Study Group.

Clin Infect Dis. 2009 Sep 15;49(6):892-900. doi: 10.1086/605440.

PMID:
19663689
6.
8.

Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.

Hammond E, McKinnon E, Nolan D.

Clin Infect Dis. 2010 Sep 1;51(5):591-9. doi: 10.1086/655765.

PMID:
20645860
9.

Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz.

Viganò A, Brambilla P, Cafarelli L, Giacomet V, Borgonovo S, Zamproni I, Zuccotti G, Mora S.

Antivir Ther. 2007;12(3):297-302.

PMID:
17591019
10.

Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).

Ribera E, Paradiñeiro JC, Curran A, Sauleda S, García-Arumí E, Castella E, Puiggròs C, Crespo M, Feijoo M, Diaz M, Del Saz SV, Planas M, Sureda D, Falcó V, Ocaña I, Pahissa A.

HIV Clin Trials. 2008 Nov-Dec;9(6):407-17. doi: 10.1310/hct0906-407.

PMID:
19203906
11.

[Tenofovir as a strategy to avoid or limit adverse effects].

Portilla J.

Enferm Infecc Microbiol Clin. 2008 Jun;26 Suppl 8:19-24. Review. Spanish.

PMID:
19195434
12.

Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.

Tavassoli N, Bagheri H, Sommet A, Delpierre C, Marion-Latard F, Massip P, Aquilina C, Bonnet E, Obadia M, Labau E, Montastruc JL, Bernard J.

Pharmacotherapy. 2006 Feb;26(2):154-61.

PMID:
16466321
13.

Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.

Buffet M, Schwarzinger M, Amellal B, Gourlain K, Bui P, Prévot M, Deleuze J, Morini JP, Gorin I, Calvez V, Dupin N.

J Clin Virol. 2005 May;33(1):60-4.

PMID:
15797366
14.

Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level.

Nolan D, Hammond E, James I, McKinnon E, Mallal S.

Antivir Ther. 2003 Dec;8(6):617-26.

PMID:
14760896
15.

Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens.

Jones SP, Qazi N, Morelese J, Lebrecht D, Sutinen J, Yki-Jărvinen H, Back DJ, Pirmohamed M, Gazzard BG, Walker UA, Moyle GJ.

J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):565-72.

PMID:
16284533
17.

Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial.

Curran A, Martinez E, Podzamczer D, Lonca M, Barragan P, Crespo M, Falco V, Vidal-Sicart S, Imaz A, Martinez M, Gatell JM, Ribera E.

Antivir Ther. 2012;17(4):711-8. doi: 10.3851/IMP2081. Epub 2012 Feb 28.

PMID:
22374987
18.

Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.

Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel FD, Knysz B, Antunes F, Reiss P, Lundgren JD.

AIDS. 2006 May 12;20(8):1141-50.

PMID:
16691065
19.

Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy.

Casula M, Weverling GJ, Wit FW, Timmermans EC, Stek M Jr, Lange JM, Reiss P.

J Infect Dis. 2005 Nov 15;192(10):1794-800. Epub 2005 Oct 12.

PMID:
16235179
20.

Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir.

McComsey GA, O'Riordan M, Choi J, Libutti D, Rowe D, Storer N, Harrill D, Gerschenson M.

Antivir Ther. 2012;17(2):347-53. doi: 10.3851/IMP1928. Epub 2011 Oct 13.

Supplemental Content

Support Center